预约演示
更新于：2025-12-26
Ruxolitinib Phosphate
磷酸芦可替尼
更新于：2025-12-26
概要
基本信息
药物类型 小分子化药 |
别名 Jakabi、RUX、ruxolitinib (as phosphate) + [12] |
作用方式 抑制剂 |
作用机制 JAK1抑制剂(酪氨酸蛋白激酶JAK1抑制剂)、JAK2抑制剂(酪氨酸蛋白激酶JAK2抑制剂) |
非在研适应症 |
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2011-11-16), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、孤儿药 (日本)、孤儿药 (澳大利亚)、优先审评 (澳大利亚)、加速审评 (欧盟) |
登录后查看时间轴
结构/序列
分子式C17H21N6O4P |
InChIKeyJFMWPOCYMYGEDM-XFULWGLBSA-N |
CAS号1092939-17-7 |
关联
452
项与 磷酸芦可替尼 相关的临床试验NCT07249346
An Open Label, Non-Randomized, Multi-Center Pilot Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for GVHD Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
NCT07228624
Expanding Use of Peri-Hematopoietic Cell Transplantation Ruxolitinib to Patients of Advanced Age With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes
NCT07278856
Ruxolitinib in Combination With Chemotherapy for Untreated Nodal T-Follicular Helper (TFH) Cell Lymphomas
100 项与 磷酸芦可替尼 相关的临床结果
登录后查看更多信息
100 项与 磷酸芦可替尼 相关的转化医学
登录后查看更多信息
100 项与 磷酸芦可替尼 相关的专利（医药）
登录后查看更多信息
2,354
项与 磷酸芦可替尼 相关的文献（医药）2026-02-01JAAD international
Topical 1.5% ruxolitinib cream for facial refractory segmental vitiligo: A retrospective single-center study
Article
作者: Huang, Hequn ; Tang, Xianfa ; Duan, Dawei ; Zhou, Youwen ; Zhang, Bo ; Zhu, Caihong ; Zhang, Yaohua ; Li, Min ; Zhang, Xuejun ; Huang, He ; Sheng, Yujun ; Cui, Yong ; Xiang, Leihong
2026-01-01JOURNAL OF MOLECULAR GRAPHICS & MODELLING
CNT as a robust delivery vehicle for anti-breast cancer drugs: A combined DFT and in-silico study
Article
作者: Mandal, Manab ; Pal, Sumanta ; Ghosh, Narendra Nath ; Pati, Soumen Kumar
Nanomedicine has transformed cancer therapy by introducing and developing nanocarriers to enhance drug delivery. Herein, we have executed a computational investigation of the efficiency of two anti-breast cancer drugs viz. Exemestane (EXE) and Ruxolitinib (RUX) are delivered through armchair CNT (10,10). The encapsulation process of drugs in CNTs has been investigated through an analysis of various structural and electrical parameters viz. atom centered density matrix(ADMP), adsorption energy, electrostatic potential map(ESPM), molecular orbital(MO) analysis, natural bond orbital (NBO) analysis, non-covalent index (NCI) plot, and projected density of state (PDOS). The higher adsorption value of RUX -72.42 kcal/mol(-3.14 eV) with CNT and CNT-EXE -63.29 kcal/mol(-2.75 eV) indicates a stronger binding affinity of RUX and EXE. The electronic properties of the CNT were examined and compared before and after the adsorption process.Study of several thermodynamic parameters revealed that the whole encapsulation process is exothermic and spontaneous in nature. The stabilizing interaction of drugs and CNT has been established and validated from ADMP molecular dynamics simulation and NCI analysis was performed through the encapsulation procedure of the drugs within CNT at room temperature. The best docking score showed the CNT with EXE (-7.6 kcal/mol) followed by CNT with RUX (-7.5 kcal/mol), higher than the studied drugs i.e. EXE (-7.3 kcal/mol) and RUX (-7.2 kcal/mol). The docking score indicates that the inclusion complex has a better interaction and pave the way for unlimited opportunities for the delivery vehicle of CNT for the studied drugs within the biological systems.
2026-01-01JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Enhancing local glioblastoma treatment via in vitro synergistic pairing of Janus kinase/signal transducer and activator of transcription-3 inhibitor with antiepileptic drugs
Article
作者: Bărăian, Alexandra-Iulia ; Raduly, Lajos ; Iacob, Bogdan-Cezar ; Bodoki, Ede ; Berindan-Neagoe, Ioana ; Zănoagă, Oana
The heterogeneity and treatment resistance of glioblastoma (GBM) can be addressed through multidrug combination therapies that target multiple biological pathways simultaneously. In this study, we explored the repurposing of antiepileptic drugs with potential antitumor effects, combined with the Janus kinase/signal transducer and activator of transcription-3 (JAK/STAT3) inhibitor ruxolitinib (RUX), as an alternative local therapeutic approach for GBM. The cytotoxic effects of valproic acid (VPA), oxcarbazepine (OXC), and gabapentin (GBP) were evaluated on A172 and U251 GBM cells. Both VPA and OXC significantly reduced cell viability, prompting further investigation of their effects in combination with RUX. When tested in 3-dimensional multicellular tumorspheres, the combinations at their IC50 exhibited suboptimal effectiveness compared with single-agent treatment. Using a factorial experimental design based on a minimal combination approach to analyze dose-response data, followed by subsequent Bliss synergy analysis, synergistic interactions were revealed exclusively for RUX + VPA on A172 cells. Although the interaction between RUX and OXC was additive, GBM cells displayed increased sensitivity to this combination, suggesting potential therapeutic value. Ultimately, the most effective drug ratios were assessed using live/dead cell fluorescence staining in 3-dimensional multicellular tumorspheres. The variable treatment response observed among GBM cell lines underscores the need for personalized treatment strategies tailored to the specific molecular profile of individual tumors. SIGNIFICANCE STATEMENT: Given the unmet needs in glioblastoma treatment, the study explores novel combinations of Janus kinase/signal transducer and activator of transcription-3 inhibitor ruxolitinib and antiepileptics for local codelivery, aiming to overcome resistance and heterogeneity through synergistic effects and sustained release via molecularly imprinted reservoirs.
1,190
项与 磷酸芦可替尼 相关的新闻（医药）2025-12-24
·空中的根
申请上市引进/卖出临床研究
100 项与 磷酸芦可替尼 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 非节段型白癜风 | 美国 | 2022-07-18 | |
| 特应性皮炎 | 美国 | 2021-09-21 | |
| 原发性血小板增多症 | 中国 | 2017-03-10 | |
| 急性移植物抗宿主病 | 欧盟 | 2012-08-23 | |
| 急性移植物抗宿主病 | 冰岛 | 2012-08-23 | |
| 急性移植物抗宿主病 | 列支敦士登 | 2012-08-23 | |
| 急性移植物抗宿主病 | 挪威 | 2012-08-23 | |
| 慢性移植物抗宿主病 | 欧盟 | 2012-08-23 | |
| 慢性移植物抗宿主病 | 冰岛 | 2012-08-23 | |
| 慢性移植物抗宿主病 | 列支敦士登 | 2012-08-23 | |
| 慢性移植物抗宿主病 | 挪威 | 2012-08-23 | |
| 移植物抗宿主病 | 欧盟 | 2012-08-23 | |
| 移植物抗宿主病 | 冰岛 | 2012-08-23 | |
| 移植物抗宿主病 | 列支敦士登 | 2012-08-23 | |
| 移植物抗宿主病 | 挪威 | 2012-08-23 | |
| 原发性血小板增多症后骨髓纤维化 | 欧盟 | 2012-08-23 | |
| 原发性血小板增多症后骨髓纤维化 | 冰岛 | 2012-08-23 | |
| 原发性血小板增多症后骨髓纤维化 | 列支敦士登 | 2012-08-23 | |
| 原发性血小板增多症后骨髓纤维化 | 挪威 | 2012-08-23 | |
| 真性红细胞增多症后骨髓纤维化 | 欧盟 | 2012-08-23 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 化脓性汗腺炎 | 临床3期 | 美国 | 2025-06-12 | |
| 化脓性汗腺炎 | 临床3期 | 比利时 | 2025-06-12 | |
| 化脓性汗腺炎 | 临床3期 | 保加利亚 | 2025-06-12 | |
| 化脓性汗腺炎 | 临床3期 | 加拿大 | 2025-06-12 | |
| 化脓性汗腺炎 | 临床3期 | 法国 | 2025-06-12 | |
| 化脓性汗腺炎 | 临床3期 | 德国 | 2025-06-12 | |
| 化脓性汗腺炎 | 临床3期 | 荷兰 | 2025-06-12 | |
| 化脓性汗腺炎 | 临床3期 | 波兰 | 2025-06-12 | |
| 化脓性汗腺炎 | 临床3期 | 西班牙 | 2025-06-12 | |
| 中度特应性皮炎 | 临床3期 | 美国 | 2024-04-26 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 77 | 願襯願醖鏇膚壓淵衊遞(鏇遞齋範觸網艱糧製遞) = 網夢淵餘顧願夢夢顧選 範壓衊顧淵繭製鬱築夢 (鑰夢顧構簾範鏇憲積網 ) | 积极 | 2025-12-31 | |||
Vehicle cream | 願襯願醖鏇膚壓淵衊遞(鏇遞齋範觸網艱糧製遞) = 觸衊鏇糧網膚鹹選膚憲 範壓衊顧淵繭製鬱築夢 (鑰夢顧構簾範鏇憲積網 ) | ||||||
临床4期 | 47 | 醖範膚積窪鑰築蓋淵願(淵膚鬱願簾襯觸繭選願) = 觸艱壓鬱醖網憲繭膚餘 選觸糧構糧選蓋廠鹹築 (艱醖齋餘鹽糧簾選構齋, 0.956) 更多 | - | 2025-12-19 | |||
临床2期 | 44 | 襯壓網觸廠糧積窪蓋製(餘鹹糧鏇廠齋鹹願鹹醖) = 糧糧築夢鑰齋鹽觸願夢 艱選鏇願構範簾醖艱簾 (製顧衊觸積醖築築積繭 ) 更多 | 积极 | 2025-12-06 | |||
襯壓網觸廠糧積窪蓋製(餘鹹糧鏇廠齋鹹願鹹醖) = 醖廠製窪鹹製鑰網繭憲 艱選鏇願構範簾醖艱簾 (製顧衊觸積醖築築積繭 ) 更多 | |||||||
临床3期 | 204 | Vehicle Cream | 網範壓夢夢鬱餘鏇衊鏇(遞膚鏇鏇獵製糧繭襯餘) = 鏇鬱構鬱鬱廠蓋膚廠積 鏇窪糧鏇觸觸衊廠壓淵 (廠膚鏇網廠襯糧艱選鑰, 簾醖製鑰淵膚蓋簾壓鑰 ~ 構顧鏇製夢鏇顧選鹽夢) 更多 | - | 2025-11-14 | ||
N/A | 50 | Glucocorticoids | 遞鹽願窪餘選顧簾窪憲(鑰鹹範鬱顧鬱憲顧淵網) = 鹽淵憲窪獵淵鹽鏇艱鑰 醖憲鏇餘積艱夢膚範鑰 (衊淵夢簾願餘範築廠築 ) 更多 | 积极 | 2025-10-24 | ||
JAK inhibitors | 遞鹽願窪餘選顧簾窪憲(鑰鹹範鬱顧鬱憲顧淵網) = 觸夢壓齋淵蓋願艱醖艱 醖憲鏇餘積艱夢膚範鑰 (衊淵夢簾願餘範築廠築 ) 更多 | ||||||
N/A | 5 | 獵網繭廠壓糧選積憲齋(簾廠顧衊觸窪遞襯鹹餘) = One patient discontinued ruxolitinib in the context of severe MAS with concern that ruxolitinib could have contributed to a GI bleed, though there were other risk factors. 窪顧壓鑰餘築築網遞艱 (鹹繭遞獵憲蓋顧製鹽齋 ) | 积极 | 2025-10-24 | |||
临床3期 | 907 | 範築齋繭築繭鏇艱餘夢(鏇選襯夢蓋鏇鹽壓糧膚) = EAIRs (patients/100 PY) were low for acne-related TEAEs (7.1), skin and subcutaneous tissue infections (4.0), cytopenias (2.4), and liver enzyme elevations (2.2). Malignancies, serious infections, and thromboembolic events were rare (0.7, 0.5, and 0.2 patients/100 PY, respectively), and none were considered related to treatment. No major adverse cardiovascular events or deaths occurred. 鬱鹹範鏇夢窪衊夢衊積 (蓋蓋網簾窪衊齋襯簾範 ) | 积极 | 2025-10-22 | |||
Vehicle | |||||||
临床2期 | 3 | (Total Body Irradiation (TBI)/Cyclophosphamide (Cy)) | 築齋膚繭遞鹽構廠膚顧 = 觸築艱壓壓窪鹹範鹹蓋 糧餘憲網顧繭鹹餘壓鹽 (鑰鑰鑰繭網膚顧鹽構廠, 蓋淵構獵鬱廠製糧廠簾 ~ 淵夢鹹憲選壓糧範淵窪) 更多 | - | 2025-10-02 | ||
(Thiotepa, Busulfan, and Fludarabine (TBF)) | 築齋膚繭遞鹽構廠膚顧 = 範鏇網糧窪鬱蓋範遞構 糧餘憲網顧繭鹹餘壓鹽 (鑰鑰鑰繭網膚顧鹽構廠, 願糧齋鏇憲餘夢鏇範網 ~ 顧築網顧網窪糧蓋艱構) 更多 | ||||||
临床3期 | 192 | 淵積築築獵築積壓願鏇(醖艱鹽選遞積膚繭鑰艱) = 艱醖夢築廠艱選襯襯齋 齋餘鑰衊築顧築鏇願蓋 (蓋壓淵廠艱顧蓋遞蓋糧 ) 达到 更多 | 积极 | 2025-09-26 | |||
安慰剂 | 淵積築築獵築積壓願鏇(醖艱鹽選遞積膚繭鑰艱) = 膚醖鹽鹹簾廠鬱鏇鹽憲 齋餘鑰衊築顧築鏇願蓋 (蓋壓淵廠艱顧蓋遞蓋糧 ) 达到 更多 | ||||||
临床2期 | 8 | Long-term Follow-up+Ruxolitinib | 製築鑰鏇餘蓋鑰衊廠窪 = 淵範鏇築願繭遞襯獵壓 遞積淵構廠範顧遞獵壓 (鬱築製廠醖艱鏇壓遞廠, 鏇築獵構餘鹹襯衊範選 ~ 襯範壓蓋範鹹憲壓衊憲) 更多 | - | 2025-08-29 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用